Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO-GRAIL: Gradual interval prolongation of biological therapy in severe asthma
2025-524741-28-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mepolizumab, reslizumab, benralizumab, dupilumab and tezepelumab in severe asthma, sponsored by Amsterdam University Medical Center. Primary endpoint: Maintained asthma control after ~1 year with at least one interval prolongation step. Planned start Jun 2026; status: authorised.
02
Drugs
03
Conditions
severe asthma
Beyond the preview
Go deeper on 2025-524741-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524741-28-00.